RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

August 10, 2017

Primary Completion Date

March 31, 2026

Study Completion Date

April 30, 2026

Conditions
Vomiting in Infants and/or ChildrenNauseaHematopoietic System--CancerOncology
Interventions
DRUG

Olanzapine

olanzapine 0.1 mg/kg/dose (maximum 10 mg/dose) by mouth as a single daily dose based on actual body weight

DRUG

Placebo Oral Tablet

Placebo tablets that look like olanzapine and will be dosed as if they are olanzapine

Trial Locations (10)

10032

WITHDRAWN

Columbia University/Morgan Stanley Children's Hospital, New York

29425

RECRUITING

Medical University of South Carolina, Charleston

43205

RECRUITING

Nationwide Children's Hospital, Columbus

64108

RECRUITING

The Children's Mercy Hospital, Kansas City

94158

RECRUITING

University of California, San Francisco

110029

RECRUITING

All India Institute of Medical Sciences, New Delhi

27599-7220

RECRUITING

University of North Carolina at Chapel Hill, Chapel Hill

R3E 0V9

RECRUITING

Cancer Care Manitoba, Winnipeg

M5G 1X8

RECRUITING

Hospital for Sick Children, Toronto

H3T 1C5

TERMINATED

Centre Hospitalier Universitaire Sainte-Justine,, Montreal

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University of California, San Francisco

OTHER

collaborator

Children's Mercy Hospital Kansas City

OTHER

collaborator

St. Justine's Hospital

OTHER

collaborator

Columbia University

OTHER

collaborator

Medical University of South Carolina

OTHER

collaborator

CancerCare Manitoba

OTHER

collaborator

University of North Carolina, Chapel Hill

OTHER

collaborator

Nationwide Children's Hospital

OTHER

lead

The Hospital for Sick Children

OTHER